Abstract
Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
Keywords: amitriptyline, amygdala, cingulate, citalopram, doxepine, fluoxetine, fluxovamine, hippocampus, mirtazapine, paroxetine, prefrontal cortex, reboxetine, sertraline, trimipramine, venlafaxine.
Current Neuropharmacology
Title:Brain Structural Effects of Antidepressant Treatment in Major Depression
Volume: 13 Issue: 4
Author(s): Nicola Dusi, Stefano Barlati, Antonio Vita and Paolo Brambilla
Affiliation:
Keywords: amitriptyline, amygdala, cingulate, citalopram, doxepine, fluoxetine, fluxovamine, hippocampus, mirtazapine, paroxetine, prefrontal cortex, reboxetine, sertraline, trimipramine, venlafaxine.
Abstract: Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
Export Options
About this article
Cite this article as:
Dusi Nicola, Barlati Stefano, Vita Antonio and Brambilla Paolo, Brain Structural Effects of Antidepressant Treatment in Major Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X1304150831121909
DOI https://dx.doi.org/10.2174/1570159X1304150831121909 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Pharmacogenomics of Multiple Sclerosis: Current Status and Potential Applications
Current Pharmacogenomics and Personalized Medicine Cabozantinib in Thyroid Cancer
Recent Patents on Anti-Cancer Drug Discovery Newborn Screening through TREC, TREC/KREC System for Primary Immunodeficiency with limitation of TREC/KREC. Comprehensive Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets Neurological Complications Caused by Human Immunodeficiency Virus (HIV) and Associated Opportunistic Co-infections: A Review on their Diagnosis and Therapeutic Insights
CNS & Neurological Disorders - Drug Targets Antagonism of Eosinophil Accumulation in Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment
CNS & Neurological Disorders - Drug Targets Executive Dyscontrol in Dementia, with Emphasis on Subcortical Pathology and the Role of Butyrylcholinesterase
Current Alzheimer Research Recombinant Virus Like Particles as Drug Delivery System
Current Pharmaceutical Biotechnology Insulin and the Brain
Current Diabetes Reviews Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology